Cramer on Covid omicron variant: Panic is not an investment strategy at all


CNBC’s Jim Cramer said Monday investors need to remain calm and trust in drug companies to develop any additional solutions needed to beat back the newly detected Covid omicron variant.

“When I say trust the science, that doesn’t necessarily mean … buy the stock market. But it most certainly means do not panic,” the “Mad Money” host said.

“Those who panicked and sold into the maelstrom” that was Friday’s sell-off are likely already regretting it, he added, shortly after the S&P 500 rose 1.3% on Monday.

Cramer acknowledged the omicron variant may have economic consequences and stressed the need for investors to prepare for multiple scenarios, including a slowdown that favors stocks such as Amazon.

However, at this point, Cramer said there’s no reason to make investment decisions out of fear, which he contended took place Friday when the Dow Jones Industrial Average posted its worse session since October 2020.

In addition to his faith in vaccine makers, Cramer also expressed confidence in Federal Reserve Chairman Jerome Powell to monitor the variant’s impact on the economy and to steer monetary policy accordingly.

“The last two sessions were yet another demonstration that panic is not a strategy for you. It’s not a strategy at all,” Cramer said. “Am I worried about the omicron variant? Sure, I’m not an idiot, but we’ve seen this movie before and we know how it ends.”

Sign up now for the CNBC Investing Club to follow Jim Cramer’s every move in the market.


Questions for Cramer?
Call Cramer: 1-800-743-CNBC

Want to take a deep dive into Cramer’s world? Hit him up!
Mad Money TwitterJim Cramer TwitterFacebookInstagram

Questions, comments, suggestions for the “Mad Money” website?

Products You May Like

Articles You May Like

FDA allows temporary import of unapproved Chinese cancer drug to ease U.S. shortage
Senate votes to repeal Biden’s student loan forgiveness plan. White House warns Biden will veto
Universal basic income of nearly $2,000 a month to be trialed in England for the first time
Three industries ripe for automation, according to a robotics guru
Why wealthy Americans love UBS, the secretive Swiss banking giant

Leave a Reply

Your email address will not be published. Required fields are marked *